Updated Recommendations From the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021

Details

• Personal Author:
  MacNeil, Jessica R. ; Su, John R. ; Broder, Karen R. ; Guh, Alice Y. ; Gargano, Julia W. ; Wallace, Megan ; Hadler, Stephen C. ; Scobie, Heather M. ; Blain, Amy E. ; Moulia, Danielle ; Daley, Matthew F. ; McNally, Veronica V. ; Romero, José R. ; Talbot, H. Keipp ; Lee, Grace M. ; Bell, Beth P. ; Oliver, Sara E.
  More +
• Corporate Authors:
  United States. Advisory Committee on Immunization Practices. ; CDC COVID-19 Response Team. ; Kaiser Permanente Colorado. Institute for Health Research. ; Franny Strong Foundation (West Bloomfield, Michigan) ; Arkansas. Department of Health. ; Vanderbilt University School of Medicine. ; Stanford University School of Medicine. ; University of Washington.
• Description:
  What is already known about this topic? On April 13, 2021, CDC and the Food and Drug Administration (FDA) recommended pausing use of the Janssen COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome (TTS) among vaccine recipients. ; What is added by this report? On April 23, the Advisory Committee on Immunization Practices concluded that the benefits of resuming Janssen COVID-19 vaccination among persons aged ≥18 years outweighed the risks and reaffirmed its interim recommendation under FDA’s Emergency Use Authorization, which includes a new warning for rare clotting events among women aged 18–49 years. ; What are the implications for public health practice? Resuming use of the Janssen COVID-19 vaccine will ensure flexibility, choice, and improved access. Education about TTS risk with Janssen COVID-19 vaccine is critical. ; Suggested citation for this article: MacNeil JR, Su JR, Broder KR, et al. Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021. MMWR Morb Mortal Wkly Rep. ePub: 27 April 2021. ; mm7017e4.htm?s_cid=mm7017e4_w ; mm7017e4-H.pdf
• Subjects:
  • Coronavirus Infections/prevention & control
  • COVID-19 Vaccines
  • Patient Safety
  • Viral Vaccine
• Source:
  MMWR: Morbidity and Mortality Weekly Report 2021; v. 70 Early Release
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Document Type:
  Journal Article
• Corporate as Subject:
  Janssen COVID-19 vaccine
• Place as Subject:
  United States
• Location:
  North America
• Pages in Document:
  6 pdf pages
• Volume:
  70
• Download URL:
  https://stacks.cdc.gov/view/cdc/105532/cdc_105532_DS1.pdf
• File Type:
  [PDF - 137.87 KB]
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR) ; Advisory Committee on Immunization Practices (ACIP)
• Main Document Checksum:
  urn:sha-512:07700b022752a4580959d6bd1928e14978da47e98bddd3db57dbe0098bc29d6febc2e3f537c6de791d5b8431e832eed3b79bf74dd0f6cdeb504d85b719132e26